Almirall LBTSF Stock
Almirall Price Chart
Almirall LBTSF Financial and Trading Overview
| Almirall stock price | 15.35 USD |
| Previous Close | 9.75 USD |
| Open | 15.35 USD |
| Bid | 13.38 USD x 20000 |
| Ask | 15.21 USD x 20000 |
| Day's Range | 15.35 - 15.35 USD |
| 52 Week Range | 13.36 - 15.47 USD |
| Volume | 100 USD |
| Avg. Volume | 0 USD |
| Market Cap | 3.34B USD |
| Beta (5Y Monthly) | 0.174 |
| PE Ratio (TTM) | 59.038464 |
| EPS (TTM) | 0.26 USD |
| Forward Dividend & Yield | 0.21 (1.35%) |
| Ex-Dividend Date | May 14, 2026 |
| 1y Target Est | N/A |
LBTSF Valuation Measures
| Enterprise Value | 3.35B USD |
| Trailing P/E | 59.038464 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | 0.76 |
| Price/Sales (ttm) | 2.8875208 |
| Price/Book (mrq) | 1.8937422 |
| Enterprise Value/Revenue | 2.897 |
| Enterprise Value/EBITDA | 15.203 |
Trading Information
Almirall Stock Price History
| Beta (5Y Monthly) | 0.174 |
| 52-Week Change | 14.89% |
| S&P500 52-Week Change | 18.32% |
| 52 Week High | 15.47 USD |
| 52 Week Low | 13.36 USD |
| 50-Day Moving Average | 15.35 USD |
| 200-Day Moving Average | 14.95 USD |
LBTSF Share Statistics
| Avg. Volume (3 month) | 0 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 217.61M |
| Float | 78.27M |
| Short Ratio | N/A |
| % Held by Insiders | 64.07% |
| % Held by Institutions | 17.65% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.187 |
| Trailing Annual Dividend Yield | 1.91% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.8364 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 5.11% |
| Operating Margin (ttm) | 13.33% |
| Gross Margin | 77.03% |
| EBITDA Margin | 19.05% |
Management Effectiveness
| Return on Assets (ttm) | 2.69% |
| Return on Equity (ttm) | 3.95% |
Income Statement
| Revenue (ttm) | 1.16B USD |
| Revenue Per Share (ttm) | 5.41 USD |
| Quarterly Revenue Growth (yoy) | 13.00% |
| Gross Profit (ttm) | 891.16M USD |
| EBITDA | 220.43M USD |
| Net Income Avi to Common (ttm) | 59.13M USD |
| Diluted EPS (ttm) | 0.26 |
| Quarterly Earnings Growth (yoy) | 387.10% |
Balance Sheet
| Total Cash (mrq) | 355.41M USD |
| Total Cash Per Share (mrq) | 1.63 USD |
| Total Debt (mrq) | 363.67M USD |
| Total Debt/Equity (mrq) | 23.76 USD |
| Current Ratio (mrq) | 2.308 |
| Book Value Per Share (mrq) | 8.105644 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 248.74M USD |
| Levered Free Cash Flow (ttm) | 75.25M USD |
Profile of Almirall
| Country | United States |
| State | N/A |
| City | Barcelona |
| Address | Ronda General Mitre, 151 |
| ZIP | 08022 |
| Phone | 34 93 291 30 00 |
| Website | https://www.almirall.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 2097 |
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage. It has research and development agreements with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk, and Eloxx. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
Q&A For Almirall Stock
What is a current LBTSF stock price?
Almirall LBTSF stock price today per share is 15.35 USD.
How to purchase Almirall stock?
You can buy LBTSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Almirall?
The stock symbol or ticker of Almirall is LBTSF.
Which industry does the Almirall company belong to?
The Almirall industry is Drug Manufacturers - Specialty & Generic.
How many shares does Almirall have in circulation?
The max supply of Almirall shares is 217.61M.
What is Almirall Price to Earnings Ratio (PE Ratio)?
Almirall PE Ratio is 59.03846400 now.
What was Almirall earnings per share over the trailing 12 months (TTM)?
Almirall EPS is 0.26 USD over the trailing 12 months.
Which sector does the Almirall company belong to?
The Almirall sector is Healthcare.
